RU2021107054A - Конденсированные бициклические соединения для лечения заболевания - Google Patents
Конденсированные бициклические соединения для лечения заболевания Download PDFInfo
- Publication number
- RU2021107054A RU2021107054A RU2021107054A RU2021107054A RU2021107054A RU 2021107054 A RU2021107054 A RU 2021107054A RU 2021107054 A RU2021107054 A RU 2021107054A RU 2021107054 A RU2021107054 A RU 2021107054A RU 2021107054 A RU2021107054 A RU 2021107054A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound according
- hydrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 8
- 201000010099 disease Diseases 0.000 title claims 5
- 150000003839 salts Chemical class 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 5
- 102100038495 Bile acid receptor Human genes 0.000 claims 4
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 230000003143 atherosclerotic effect Effects 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000007870 cholestasis Effects 0.000 claims 1
- 231100000359 cholestasis Toxicity 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562138725P | 2015-03-26 | 2015-03-26 | |
| US62/138,725 | 2015-03-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017137366A Division RU2017137366A (ru) | 2015-03-26 | 2016-03-25 | Конденсированные бициклические соединения для лечения заболевания |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2021107054A true RU2021107054A (ru) | 2021-03-31 |
Family
ID=56072361
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021107054A RU2021107054A (ru) | 2015-03-26 | 2016-03-25 | Конденсированные бициклические соединения для лечения заболевания |
| RU2017137366A RU2017137366A (ru) | 2015-03-26 | 2016-03-25 | Конденсированные бициклические соединения для лечения заболевания |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017137366A RU2017137366A (ru) | 2015-03-26 | 2016-03-25 | Конденсированные бициклические соединения для лечения заболевания |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10421759B2 (enExample) |
| EP (2) | EP3715348A1 (enExample) |
| JP (1) | JP6843061B2 (enExample) |
| KR (1) | KR20180003545A (enExample) |
| CN (1) | CN107912042A (enExample) |
| AU (2) | AU2016238523A1 (enExample) |
| BR (1) | BR112017020374A2 (enExample) |
| CA (1) | CA2980394A1 (enExample) |
| CL (1) | CL2017002405A1 (enExample) |
| CO (1) | CO2017010621A2 (enExample) |
| HK (1) | HK1249756A1 (enExample) |
| IL (1) | IL254572A0 (enExample) |
| MX (1) | MX370897B (enExample) |
| RU (2) | RU2021107054A (enExample) |
| SG (2) | SG10201908881PA (enExample) |
| WO (1) | WO2016151403A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016151403A1 (en) * | 2015-03-26 | 2016-09-29 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| EP3463373A4 (en) * | 2016-05-25 | 2020-04-22 | Akarna Therapeutics, Ltd. | COMBINATION THERAPIES WITH FARNESOID-X RECEPTOR (FRX) MODULATORS |
| BR112018074231A2 (pt) * | 2016-05-25 | 2019-03-06 | Akarna Therapeutics, Ltd. | compostos bicíclicos fundidos para o tratamento de doença |
| WO2018222876A1 (en) * | 2017-06-02 | 2018-12-06 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds |
| CN108264474B (zh) * | 2018-02-09 | 2019-10-25 | 浙江师范大学 | 一种色胺及其衍生物的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| US7595311B2 (en) | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| CA2532798C (en) * | 2003-07-23 | 2013-02-19 | X-Ceptor Therapeutics Inc. | Azepine derivatives as pharmaceutical agents |
| BRPI0514269A (pt) | 2004-08-10 | 2008-06-10 | Exelixis Inc | compostos heterocìclicos como agentes farmacêuticos |
| WO2006109633A1 (ja) | 2005-04-07 | 2006-10-19 | Daiichi Sankyo Company, Limited | 置換インドール化合物 |
| CA2633243C (en) * | 2005-12-15 | 2014-05-27 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| WO2008073825A1 (en) | 2006-12-08 | 2008-06-19 | Exelixis, Inc. | Lxr and fxr modulators |
| US20090131409A1 (en) | 2007-10-22 | 2009-05-21 | Wyeth | 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY |
| US20090137554A1 (en) | 2007-10-22 | 2009-05-28 | Wyeth | 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY |
| WO2010036362A1 (en) * | 2008-09-26 | 2010-04-01 | Wyeth | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors |
| ES2911293T3 (es) * | 2014-11-21 | 2022-05-18 | Akarna Therapeutics Ltd | Compuestos bicíclicos fusionados para el tratamiento de enfermedades |
| JP2017538773A (ja) * | 2014-12-22 | 2017-12-28 | アカーナ・セラピューティクス・リミテッドＡｋａｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｔｄ． | 疾患の処置のための縮合二環式化合物 |
| WO2016151403A1 (en) * | 2015-03-26 | 2016-09-29 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
-
2016
- 2016-03-25 WO PCT/IB2016/000606 patent/WO2016151403A1/en not_active Ceased
- 2016-03-25 MX MX2017012342A patent/MX370897B/es active IP Right Grant
- 2016-03-25 EP EP20158977.7A patent/EP3715348A1/en not_active Withdrawn
- 2016-03-25 SG SG10201908881P patent/SG10201908881PA/en unknown
- 2016-03-25 KR KR1020177030777A patent/KR20180003545A/ko not_active Ceased
- 2016-03-25 JP JP2017550113A patent/JP6843061B2/ja not_active Expired - Fee Related
- 2016-03-25 CA CA2980394A patent/CA2980394A1/en not_active Abandoned
- 2016-03-25 CN CN201680029952.3A patent/CN107912042A/zh active Pending
- 2016-03-25 RU RU2021107054A patent/RU2021107054A/ru unknown
- 2016-03-25 HK HK18109050.8A patent/HK1249756A1/zh unknown
- 2016-03-25 BR BR112017020374A patent/BR112017020374A2/pt not_active IP Right Cessation
- 2016-03-25 AU AU2016238523A patent/AU2016238523A1/en not_active Abandoned
- 2016-03-25 RU RU2017137366A patent/RU2017137366A/ru unknown
- 2016-03-25 EP EP16724699.0A patent/EP3274350A1/en not_active Withdrawn
- 2016-03-25 SG SG11201707610PA patent/SG11201707610PA/en unknown
-
2017
- 2017-09-18 IL IL254572A patent/IL254572A0/en unknown
- 2017-09-25 US US15/714,013 patent/US10421759B2/en active Active
- 2017-09-25 CL CL2017002405A patent/CL2017002405A1/es unknown
- 2017-10-18 CO CONC2017/0010621A patent/CO2017010621A2/es unknown
-
2019
- 2019-09-19 US US16/575,965 patent/US20200079782A1/en not_active Abandoned
-
2020
- 2020-10-12 AU AU2020256301A patent/AU2020256301A1/en not_active Abandoned
- 2020-11-17 US US17/099,864 patent/US20210214362A1/en not_active Abandoned
-
2022
- 2022-04-19 US US17/724,138 patent/US20230002394A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017012342A (es) | 2018-06-11 |
| JP6843061B2 (ja) | 2021-03-17 |
| MX370897B (es) | 2020-01-09 |
| AU2016238523A1 (en) | 2017-11-09 |
| EP3715348A1 (en) | 2020-09-30 |
| CN107912042A (zh) | 2018-04-13 |
| US10421759B2 (en) | 2019-09-24 |
| SG10201908881PA (en) | 2019-11-28 |
| RU2017137366A (ru) | 2019-04-26 |
| IL254572A0 (en) | 2017-11-30 |
| CO2017010621A2 (es) | 2018-01-31 |
| CL2017002405A1 (es) | 2018-04-27 |
| CA2980394A1 (en) | 2016-09-29 |
| US20180118752A1 (en) | 2018-05-03 |
| US20200079782A1 (en) | 2020-03-12 |
| WO2016151403A1 (en) | 2016-09-29 |
| SG11201707610PA (en) | 2017-10-30 |
| JP2018510876A (ja) | 2018-04-19 |
| AU2020256301A1 (en) | 2020-11-05 |
| US20210214362A1 (en) | 2021-07-15 |
| US20230002394A1 (en) | 2023-01-05 |
| HK1249756A1 (zh) | 2018-11-09 |
| EP3274350A1 (en) | 2018-01-31 |
| RU2017137366A3 (enExample) | 2019-07-17 |
| KR20180003545A (ko) | 2018-01-09 |
| BR112017020374A2 (pt) | 2018-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2021100040A (ru) | Конденсированные бициклические соединения для лечения заболевания | |
| RU2017121588A (ru) | Конденсированные бициклические соединения для лечения заболевания | |
| JP2011515341A5 (enExample) | ||
| RU2500673C2 (ru) | Гетероциклические ингибиторы мек и способы их применения | |
| JP2017538773A5 (enExample) | ||
| RU2460730C2 (ru) | Новые производные n-(8-гетероарилтетрагидронафталин-2-ил)-или n-(5-гетероарилхроман-3-ил)-карбоксамида для лечения боли | |
| RU2004139063A (ru) | Ингибиторы 11-бэта-гидроксистероидной дегидрогеназы 1, полезные для лечения сахарного диабета, ожирения и дислипидемии | |
| RU2015133310A (ru) | Модуляторы натриевого канала для лечения боли | |
| JP2016512844A5 (enExample) | ||
| HRP20120447T1 (hr) | 5-supstituirani derivati kinazolinona kao protutumorska sredstva | |
| RU2018120728A (ru) | Лечение остеоартрита | |
| ME02766B (me) | Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene | |
| PE20091694A1 (es) | DERIVADOS POLISUSTITUIDOS DE 6-HETEROARIL-IMIDAZO[1,2-a] PIRIDINAS COMO MODULADORES DE LOS RECEPTORES NOT Y SU PREPARACION | |
| NZ599199A (en) | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same | |
| CY1118572T1 (el) | Παραγωγο κυκλοαλκανιου | |
| JPWO2019013311A5 (enExample) | ||
| HRP20161103T1 (hr) | Kemijski spojevi | |
| RU2017131354A (ru) | Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия | |
| KR20160105812A (ko) | 술폰아미드 유도체 또는 그의 약학적으로 허용되는 산부가염 | |
| JP2008513516A5 (enExample) | ||
| JP2017501237A5 (enExample) | ||
| MX2015013893A (es) | Nuevo derivado de acido 3-(4-(benciloxi)fenil)hex-4-inoico, metodo de preparacion del mismo y composicion farmaceutica para la prevencion y tratamiento de la enfermedad metabolica que incluye el mismo como ingrediente activo. | |
| BR112012003464B8 (pt) | compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica | |
| RU2016115487A (ru) | Тиазолопиримидиноны в качестве модуляторов активности рецепторов nmda | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 |